# Comparison of Captisol-Enabled™ Iohexol and Omnipaque™ in Patients With Impaired Renal Function Undergoing Coronary Angiography

> **NCT04627831** · PHASE2 · WITHDRAWN · sponsor: **Ligand Pharmaceuticals**

## Conditions studied

- Contrast-induced Nephropathy

## Interventions

- **DRUG:** CE-Iohexol
- **DRUG:** Iohexol

## Key facts

- **NCT ID:** NCT04627831
- **Lead sponsor:** Ligand Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-01
- **Primary completion:** 2023-03
- **Final completion:** 2023-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Internal decision
- **Last updated:** 2022-04-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04627831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04627831, "Comparison of Captisol-Enabled™ Iohexol and Omnipaque™ in Patients With Impaired Renal Function Undergoing Coronary Angiography". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04627831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*